

CONTENTS

Advances in Brief

- 2293 Enhanced Oral Absorption and Decreased Elimination of Paclitaxel in Mice Cotreated with Cyclosporin A.** Judith van Asperen, Olaf van Tellingen, Martin A. van der Valk, Michä Rozenhart, and Jos H. Beijnen.
- 2299 Response of MCF7 Human Breast Cancer to Tamoxifen: Evaluation by the Three-Time-Point, Contrast-enhanced Magnetic Resonance Imaging Method.** Edna Furman-Haran, Dov Grobged, Raanan Margalit, and Hadassa Degani.

Regular Articles

- 2305 Angiogenic Activity of Cervical Carcinoma: Assessment by Functional Magnetic Resonance Imaging-based Parameters and a Histomorphological Approach in Correlation with Disease Outcome.** Hans Hawighorst, Wolfgang Weikel, Paul G. Knapstein, Michael V. Knopp, Ivan Zuna, Stefan O. Schönberg, Peter Vaupel, and Gerhard van Kaick.
- 2313 Similar Bioavailability of Single-Dose Oral and Intravenous Mesna in the Blood and Urine of Healthy Human Subjects.** Marshall P. Goren, Jean-Marie Houle, Dorothy A. Bush, Jackie T. Li, Christopher E. Newman, and Wolfgang P. Brade.
- 2321 Phase I Trial of Cremophor EL with Bolus Doxorubicin.** Michael J. Millward, Lorraine K. Webster, Danny Rischin, Kerrie H. Stokes, Guy C. Toner, James F. Bishop, Ian N. Olver, Bernadette M. Linahan, Martha E. Linsenmeyer, and David M. Woodcock.
- 2331 bcl-2 but not p53 Expression Is Associated with Resistance to Chemotherapy in Advanced Breast Cancer.** Andrea Bonetti, Marta Zaninelli, Roberto Leone, Gian Luigi Cetto, Giuseppe Pelosi, Sonia Biolo, Alessandra Menghi, Erminia Manfrin, Franco Bonetti, and Quirino Piubello.
- 2337 Signal Transduction Abnormalities in T Lymphocytes from Patients with Advanced Renal Carcinoma: Clinical Relevance and Effects of Cytokine Therapy.** Ronald M. Bukowski, Patricia Rayman, Robert Uzzo, Tracy Bloom, Kati Sandstrom, David Peereboom, Thomas Olencki, G. Thomas Budd, Denise McLain, Paul Elson, Andrew Novick, and James H. Finke.
- 2349 Cellular but not Plasma Pharmacokinetics of Lometrexol Correlate with the Occurrence of Cumulative Hematological Toxicity.** Timothy W. Synold, Edward M. Newman, Mary Carroll, Franco M. Muggia, Susan Groshen, Kay Johnson, and James H. Doroshow.
- 2357 Augmented Capillary Leak during Isolated Hepatic Perfusion (IHP) Occurs via Tumor Necrosis Factor-independent Mechanisms.** H. Richard Alexander, Charles K. Brown, David L. Bartlett, Steven K. Libutti, William D. Figg, Sangeeta Rajé, and Ewa Turner.
- 2363 Enhancement of Cell-mediated Immunity in Melanoma Patients Immunized with Murine Anti-Idiotypic Monoclonal Antibodies (MELIMMUNE®) That Mimic the High Molecular Weight Proteoglycan Antigen.** Michael W. Pride, Steve Shuey, Antonio Grillo-Lopez, Gary Braslawsky, Merrick Ross, Sewa S. Legha, Omar Eton, Antonio Buzaid, Constantine Ioannides, and James L. Murray.

- 2371 High Basal Level Gene Expression of Thymidine Phosphorylase (Platelet-derived Endothelial Cell Growth Factor) in Colorectal Tumors Is Associated with Nonresponse to 5-Fluorouracil.** Ralf Metzger, Kathleen Danenberg, C. Gail Leichman, Dennis Salonga, Edward L. Schwartz, Scott Wadler, Heinz-Josef Lenz, Susan Groshen, Lawrence Leichman, and Peter V. Danenberg.
- 2377 Overexpression of Cyclin D1 Is Associated with Poor Prognosis in Extremity Soft-Tissue Sarcomas.** Steve H. Kim, Jonathan J. Lewis, Murray F. Brennan, James M. Woodruff, Maria Dudas, and Carlos Cordon-Cardo.
- 2383 Epidermal Growth Factor Receptor and Labeling Index Are Independent Prognostic Factors in Glial Tumor Outcome.** Marie-Christine Etienne, Jean-Louis Formento, Christine Lebrun-Frenay, Jeanine Gioanni, Marcel Chatel, Philippe Paquis, Christine Bernard, Adel Courdi, René-Jean Bensadoun, Jean-Philippe Pignol, Mireille Francoual, Patrick Grellier, Marc Frenay, and Gérard Milano.
- 2391 Activated Calphostin C Cytotoxicity Is Independent of p53 Status and *in Vivo* Metastatic Potential.** Zita Dubauskas, Traci P. Beck, Steven J. Chmura, David A. Kovar, Mithra M. Kadkhodaian, Maneesh Shrivastav, Theodore Chung, Walter M. Stadler, and Carrie W. Rinker-Schaeffer.
- 2399 *Ex Vivo* Activity of Methotrexate versus Novel Antifolate Inhibitors of Dihydrofolate Reductase and Thymidylate Synthase against Childhood Leukemia Cells.** Robert Mauritz, Marcel W. Bekkenk, Marianne G. Rots, Rob Pieters, Enrico Mini, Christina H. van Zantwijk, Anjo J. P. Veerman, Godefridus J. Peters, and Gerrit Jansen.
- 2411 Polymorphism within the Cyclin D1 Gene Is Associated with Prognosis in Patients with Squamous Cell Carcinoma of the Head and Neck.** Christoph Matthias, Kate Branigan, Volker Jahnke, Korinna Leder, Judith Haas, Jim Heighway, Peter W. Jones, Richard C. Strange, Anthony A. Fryer, and Paul R. Hoban.
- 2419 Expression of Cadherin-6 as a Novel Diagnostic Tool To Predict Prognosis of Patients with E-Cadherin-absent Renal Cell Carcinoma.** Toru Shimazui, Egbert Oosterwijk, Hideyukiz Akaza, Pierre Paul Bringuier, Emiel Ruijter, Hans van Berkel, Jeannette Oosterwijk Wakka, Adrie van Bokhoven, Frans M. J. Debruyne, and Jack A. Schalken.
- 2425 Differential Interleukin 12 Responsiveness for Interferon γ Production in Advanced Stages of Cancer Patients Correlates with Performance Status.** Kazuko Uno, Junko Setoguchi, Mari Tanigawa, Atsuko Kishi, Makoto Ogawa, Hideo Saotome, Hiromi Fujiwara, and Tsunataro Kishida.
- 2433 Frequency of Germline and Somatic BRCA1 Mutations in Ovarian Cancer.** Andrew Berchuck, Kerrie-Ann Heron, Michael E. Carney, Johnathan M. Lancaster, Elisa G. Fraser, Vickie L. Vinson, Amie M. Deffenbaugh, Alexander Miron, Jeffrey R. Marks, P. Andrew Futreal, and Tom S. Frank.
- 2439 Association of Glutathione S-Transferase *GSTM1* and *GSTT1* Null Genotypes with Clinical Outcome in Epithelial Ovarian Cancer.** Robert E. J. Howells, Charles W. E. Redman, Kalyan K. Dhar, Panos Sarhanis, Carolyn Musgrove, Peter W. Jones, Julie Alldersea, Anthony A. Fryer, Paul R. Hoban, and Richard C. Strange.

- 2447 Allelic Deletion Analyses of *MMAC/PTEN* and *DMBT1* Loci in Gliomas: Relationship to Prognostic Significance.** Huai Lin, Melissa L. Bondy, Lauren A. Langford, Kenneth R. Hess, George L. Delclos, Xifeng Wu, Wenyaw Chan, Mark A. Pershouse, W. K. Alfred Yung, and Peter A. Steck.
- 2455 Basic Fibroblast Growth Factor Enhancement of Adenovirus-mediated Delivery of the Herpes Simplex Virus Thymidine Kinase Gene Results in Augmented Therapeutic Benefit in a Murine Model of Ovarian Cancer.** Claudine Rancourt, Buck E. Rogers, Barbara A. Sosnowski, Minghui Wang, Alain Piché, Glenn F. Pierce, Ronald D. Alvarez, Gene P. Siegal, Joanne T. Douglas, and David T. Curiel.
- 2463 Inhibition of Human Glioblastoma Cell Adhesion and Invasion by 4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-Bromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).** Rama Krishna Narla, Xing-Ping Liu, Daniel Klis, and Fatih M. Uckun.
- 2473 Effect of the Combined Treatment with 5-Fluorouracil, γ -Interferon or Folinic Acid on Carcinoembryonic Antigen Expression in Colon Cancer Cells.** Angelo Aquino, Salvatore P. Prete, John W. Greiner, Anna Giuliani, Grazia Graziani, Mario Turriziani, Rosaria De Filippi, Giovanna Masci, Enzo Bonmassar, and Liana De Vecchis.
- 2483 Comparison of 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-Peptide-ChL6, a Novel Immunconjugate with Catabolizable Linker, to 2-Iminothiolane-2-[p-(Bromoacetamido)benzyl]-DOTA-ChL6 in Breast Cancer Xenografts.** Gerald L. DeNardo, Linda A. Kroger, Claude F. Meares, Carol M. Richman, Qansy Salako, Sui Shen, Kathleen R. Lamborn, James J. Peterson, Laird A. Miers, Gao Ren Zhong, and Sally J. DeNardo.
- 2491 Multifocal Renal Cell Carcinoma: Evidence for a Common Clonal Origin.** Hideaki Miyake, Hideo Nakamura, Isao Hara, Kazuo Gohji, Soichi Arakawa, Sadao Kamidono, and Hideyuki Saya.
- 2495 Human IgG2 Constant Region Enhances *in Vivo* Stability of Anti-Tenascin Antibody 81C6 Compared with Its Murine Parent.** Craig J. Reist, Darell D. Bigner, and Michael R. Zalutsky.
- 2503 Enhanced Growth Inhibition and Differentiation of Fluorodeoxyuridine-treated Human Colon Carcinoma Cells by Phenylbutyrate.** Yicong Huang and Samuel Waxman.
- 2511 Complement Factor H or a Related Protein Is a Marker for Transitional Cell Cancer of the Bladder.** Robert Kinders, Tobin Jones, Richard Root, Connie Bruce, Heather Murchison, Michael Corey, Lawrence Williams, David Enfield, and G. Michael Hass.
- 2521 Bystander Effect in the Adenovirus-mediated Wild-Type *p53* Gene Therapy Model of Human Squamous Cell Carcinoma of the Head and Neck.** Douglas K. Frank, Mitchell J. Frederick, Ta-Jen Liu, and Gary L. Clayman.
- 2529 Search for the Optimal Schedule for the Oxaliplatin/5-Fluorouracil Association Modulated or Not by Folinic Acid: Preclinical Data.** Jean-Louis Fischel, Marie-Christine Etienne, Patricia Formento, and Gérard Milano.
- 2537 A Four-Hour Topotecan Infusion Achieves Cytotoxic Exposure throughout the Neuraxis in the Nonhuman Primate Model: Implications for Treatment of Children with Metastatic Medulloblastoma.** William C. Zamboni, Amar J. Gajjar, Timothy D. Mandrell, Stephanie L. Einhaus, Mary K. Danks, William P. Rogers, Richard L. Heideman, Peter J. Houghton, and Clinton F. Stewart.
- 2545 Cell Surface Density of p185^{c-erbB-2} Determines Susceptibility to Anti-P185^{c-erbB-2}-Ricin A Chain (RTA) Immunotoxin Therapy Alone and in Combination with Anti-P170^{EGFR}-RTA in Ovarian Cancer Cells.** G. Scott Dean, Lajos Pusztai, Feng Ji Xu, Kathy O'Briant, Karen DeSombre, Mark Conaway, Cinda M. Boyer, John Mendelsohn, and Robert C. Bast, Jr.
- 2551 Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy.** Carrie S. Dolman, Barbara M. Mueller, Holger N. Lode, Rong Xiang, Stephen D. Gillies, and Ralph A. Reisfeld.
- 2559 Annexin I Degradation in Bronchoalveolar Lavage Fluids from Healthy Smokers: A Possible Mechanism of Inflammation.** Jamboor K. Vishwanatha, Randall G. Davis, Israel Rubinstein, and Anthony Floreani.
- 2565 Expression of Mouse Mammary Tumor Virus-like *env* Gene Sequences in Human Breast Cancer.** Yue Wang, Vera Go, James F. Holland, Stella M. Melana, and Beatriz G-T. Pogo.

Letters to the Editor

- 2569 Correspondence re: S. M. Melana *et al.*, Inhibition of Cell Growth and Tolomerase Activity of Breast Cancer Cells *in Vitro* by 3'-Azido-3'-deoxythymidine. *Clin. Cancer Res.*, 4: 693-696, 1998.** Letter by Ofelia A. Olivero and Daniel E. Gomez. Reply by Stella M. Melana, James F. Holland, and Beatriz G-T. Pogo.

2571 AACR Bulletin Board

Institution of Page Charges
 1999 Annual Meeting
 Call for Nominations for 1999 AACR-Pezcoller International Award for Cancer Research
 Call for Nominations for AACR Awards
 AACR Special Conferences in Cancer Research

2572 Author Index

i Instructions for Authors

Call for Abstracts for 1999 AACR Annual Meeting

Pages 1-33

Abstract Deadline: November 6, 1998

Clinical Cancer Research

4 (10)

Clin Cancer Res 1998;4:2293-2570.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/4/10.citation>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/4/10.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.